window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 20, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

viral suppression

  • Clinical Development,Infectious Diseases,Patient Centricity,Precision medicine

    ViiV Healthcare reports 12-month data showing lotivibart maintains viral suppression in ultra long-acting HIV regimen

    ViiV Healthcare, the global specialist HIV company majority owned by [...]

    February 27, 2026
  • Clinical Development,Clinical Trials,Drug Development,Infectious Diseases,Pharmaceuticals and therapeutics,Precision medicine,Supply Chain & Logistics

    Gilead reports positive Phase 3 results for single-tablet HIV regimen

    Gilead Sciences has announced positive topline results from the Phase [...]

    November 13, 2025
  • Clinical Trials,Global health,Partnerships & Funding,Precision medicine,Research & Development,Technology and platforms

    Phase 1 trial of novel HIV vaccine begins in Africa led by local researchers

    A new investigational HIV vaccine candidate, GRAdHIVNE1, has entered Phase [...]

    August 6, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Currax highlights peer-reviewed review supporting combination approaches in obesity treatment
    Categories: Obesity, Pharmaceuticals and therapeutics, Research & Development
  • MaaT Pharma publishes real-world CHRONOS data in third-line acute GvHD
    Categories: Clinical Development, Clinical studies, Hematology, Regulatory Affairs, Research & Development
  • Symbiosis expands QC capabilities with new 30°C stability chamber
    Categories: CDMOs & Manufacturing, Facilities and infrastructure, Manufacturing, Pharmaceuticals and therapeutics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top